
Jennifer Taylor-Cousar
Physician · National Jewish Health
Credentials: · · ·
History
- 2019–Present
- 2006–2008
Pulmonary Disease





Research
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
New England Journal of Medicine · 2019 · 1,774 citations
The Lancet · 2019 · 1,152 citations
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
New England Journal of Medicine · 2017 · First of 12 authors · 626 citations

39 papers
- MS
26 papers

25 papers

25 papers

23 papers
- DN
18 papers
- JN
17 papers

17 papers
Grants
- 2023–2028
National Heart, Lung, and Blood Institute · UH3
PI · $5.2M · Pennsylvania State Univ Hershey Med Ctr
- 2023–2024
National Heart, Lung, and Blood Institute · UG3
PI · $1.9M · Pennsylvania State Univ Hershey Med Ctr
- 2011–2016
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF
National Heart, Lung, and Blood Institute · K23
Contact PI · $721.6K · National Jewish Health
- 2008–2010
University of New Mexico - General Clinical Research Center
National Center for Research Resources · M01
Project lead · $60.1K · University of New Mexico
Clinical trials
- 2021–2027
Prospective Study of Pregnancy in Women With Cystic Fibrosis
Principal investigator · Active not recruiting
Amalia Magaret
- 2019–2024
Sildenafil Exercise: Role of PDE5 Inhibition
Principal investigator · Completed · Phase 2, Phase 3
National Jewish Health
- 2019–2022
Impact of Triple Combination CFTR Therapy on Sinus Disease.
Principal investigator · Unknown
Jennifer Taylor-Cousar
- 2018–2019
Principal investigator · Completed
National Jewish Health

